Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-07-09
2000-09-05
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514 12, A01N 3712, A61K 3800
Patent
active
06114388&
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to the medical sector. More particularly, the invention relates to the use of at least one monofunctional and/or polyfunctional polylysine conjugate for the preparation of pharmaceutical compositions or combinations which are useful in the treatment of neuronal degeneration, infectious, traumatic and toxic neuropathies, degenerative diseases of the autoimmune type, neurodegenerative disorders resulting from genetic diseases, and proliferative diseases. The invention further relates to monofunctional and polyfunctional polylysine conjugates.
The majority of incapacitating chronic human diseases, such as multiple sclerosis (MS), polyarthritis (RP), neuropathy, etc., do not have a clearly defined etiology. Consequently the treatments currently practiced are still symptomatic: use of corticoids, various anti-inflammatories, immunodepressants, etc.; these medications have a large number of appreciable side effects on the patients' health. Furthermore they are of transient efficacy. No lasting improvement is observed and, in particular, there is little notable improvement in the course of these diseases.
Recent data and studies on autoimmunity (Daverat et al., 1989 (1), Amara et al., 1994 (2)) have made it possible to identify chemically defined antigenic targets by the antibodies circulating in the patients' biological fluids. The increase in these circulating immunoglobulins is linked to the course of these diseases. The antibodies no longer appear as aberrant elements but are the reflection of precise antigenic disorders.
By way of example, antibodies directed against conjugated oleic acid, conjugated azelaic acid, a phospholipid and cysteinyl-NO have been identified in MS (Maneta-Peyret et al., 1987 (3); Daverat et al., 1989 (1); Brochet et al., 1991 (4); Boullerne et al., 1994 (5)).
Similarly, in the case of infection with HIV, antibodies directed against fatty acids coupled by an amide linkage have been found (Amara et al., 1994 (2)).
Patent application WO 94/27151, published on Nov. 24, 1994, describes the use of at least one conjugate between on the one hand a molecule capable of being recognized by: branched C.sub.4 -C.sub.22 fatty acids; cysteine; and/or other hand a molecule of sufficient size to allow its recognition by said antibodies, such as polylysine, for the preparation of drugs intended for the treatment of AIDS.
The following have also been described: an antibody directed against choline-glutaryl-poly-L-lysine, which mimics acetylcholine (Geffard et al., 1985 (11); Souan et al., 1986 (12)), R-glutaraldehyde-polylysine antisera, in which R is an indolealkylamine compound, which are directed against indolealkylamines (Geffard et al., 1985 (13)), and antibodies directed against .gamma.-aminobutyric acid (Geffard et al., 1985 (14); Seguela et al., 1984 (15)) and an aspartate-polylysine conjugate used in the immunochemical characterization of polyclonal antibodies directed against conjugated aspartate (Campistron et al., 1986 (21)).
Oxidative processes have been found in the course of the chronic diseases mentioned above and have been described (Buttke et al., 1994 (6)). Thus, in MS, authors have shown a direct increase in the lipoperoxidation products (Hunter et al., 1985 (7), Korpela et al., 1989 (8)) and a notable drop in the antioxidants.
Recent data have shown that, in the course of HIV infection, oxidative stress is one of the determining factors in cell death, i.e. the loss of TCD4.sup.+ lymphocytes (Roederer et al., 1993 (9), Staal et al., 1992 (10)).
It was therefore essential to provide patients with drugs having the following three objectives: chronic human disease; progressive chronic diseases.
The Applicant has solved this problem by using monofunctional and/or polyfunctional poly-L-lysine conjugates for therapeutic purposes.
According to a first feature, the present invention therefore relates to the use of at least one monofunctional and/or polyfunctional poly-L-lysine conjugate for the preparation of pharmaceutical compositions or combinations which ar
REFERENCES:
Hammermeister et al. Biochim. Biophys. Acta, 332 (2), 125-130 (Abstract), 1974.
Kawai et al. J. Macromol. Sci., Phys., B 17 (4), 653-81 (Abstract), 1980.
Citro et al., Br. J. Cancer (1994), 69(3), 463-7.
Kammeyer et al., Journal of Immunological Methods (1992), 156, 61-67.
Seguela et al., Pro. Natl. Acad. Sci. USA (1984), 81, 3888-3892.
Campistron et al., Brain Research (1), 179-84.
LandOfFree
Monofunctional and/or polyfunctional polylysine conjuages does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monofunctional and/or polyfunctional polylysine conjuages, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monofunctional and/or polyfunctional polylysine conjuages will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212628